Previous Next Accountability Ethical Issues Raised Over FDA Collaboration with Biogen on Failed Drug Abstract: The FDA collaborated with Biogen to conduct repeated re-analyses of aducanumab for Alzheimer's and FDA committee members are raising concerns. Publication: Mad in America Date Published: May 11, 2021 Author(s): Peter Simons View This Resource